STAAR Surgical (NASDAQ:STAA) Rating Lowered to “Neutral” at BTIG Research

STAAR Surgical (NASDAQ:STAA) was downgraded by analysts at BTIG Research from a “buy” rating to a “neutral” rating in a note issued to investors on Wednesday,Briefing.com Automated Import reports.

A number of other research analysts also recently issued reports on STAA. Stephens upgraded STAAR Surgical to a “hold” rating in a research note on Monday, December 2nd. William Blair cut STAAR Surgical from an “outperform” rating to a “market perform” rating in a report on Wednesday. Canaccord Genuity Group lowered their price target on STAAR Surgical from $31.00 to $28.00 and set a “hold” rating on the stock in a report on Monday, December 9th. Finally, Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a report on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $36.50.

STAAR Surgical Trading Down 3.2 %

Shares of NASDAQ:STAA opened at $21.88 on Wednesday. The stock has a 50 day moving average of $23.94 and a 200 day moving average of $29.33. The company has a market cap of $1.08 billion, a PE ratio of 49.73 and a beta of 0.62. STAAR Surgical has a 12-month low of $21.13 and a 12-month high of $52.68.

Insider Transactions at STAAR Surgical

In other news, major shareholder Broadwood Partners, L.P. acquired 8,221 shares of the firm’s stock in a transaction dated Thursday, January 16th. The shares were acquired at an average cost of $21.50 per share, with a total value of $176,751.50. Following the acquisition, the insider now directly owns 10,878,007 shares of the company’s stock, valued at approximately $233,877,150.50. The trade was a 0.08 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders have bought 105,876 shares of company stock valued at $2,487,168 in the last ninety days. Corporate insiders own 1.00% of the company’s stock.

Institutional Trading of STAAR Surgical

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC raised its holdings in STAAR Surgical by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier’s stock valued at $43,641,000 after buying an additional 31,212 shares during the period. HighTower Advisors LLC bought a new position in STAAR Surgical in the 3rd quarter valued at $336,000. Polar Asset Management Partners Inc. grew its position in STAAR Surgical by 44.3% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 168,800 shares of the medical instruments supplier’s stock valued at $6,271,000 after acquiring an additional 51,800 shares during the last quarter. JPMorgan Chase & Co. grew its position in STAAR Surgical by 411.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock valued at $7,978,000 after acquiring an additional 172,779 shares during the last quarter. Finally, Cetera Investment Advisers bought a new position in STAAR Surgical in the 2nd quarter valued at $1,135,000. Hedge funds and other institutional investors own 96.70% of the company’s stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.